Mounjaro vs. Ozempic: trial results, side effects, dosing and cost, side by side

Mounjaro vs. Ozempic comes down to two once-weekly injections for type 2 diabetes: Mounjaro is tirzepatide and Ozempic is semaglutide.1,2 Neither is FDA-approved for weight loss, although people lost weight on both in diabetes trials.

This guide covers the large trial that compared them directly, where their labels differ, and what each costs as of November 18, 2026.

Written by the FitRx care team. Last updated November 18, 2026. Sources are listed in the references.

Key takeaways

  • Mounjaro (tirzepatide) acts on GIP and GLP-1 receptors, while Ozempic (semaglutide) acts on the GLP-1 receptor only.
  • Both are approved for type 2 diabetes, not weight loss; Zepbound and Wegovy are the brands approved for weight management.
  • In the SURPASS-2 trial, adults with type 2 diabetes lost an average of 7.6 to 11.2 kg on Mounjaro and 5.7 kg on Ozempic 1 mg over 40 weeks.3
  • Both labels have a cardiovascular indication, and only Ozempic’s has a kidney indication.
  • With commercial insurance that covers them, either can cost as little as $25 with the maker’s savings program (terms as of November 18, 2026).4,5

See if you qualify

What is the difference between Mounjaro and Ozempic?

They are different medicines from different companies, and both act on the GLP-1 receptor (our GLP-1 meaning guide explains the term). The table shows the practical differences. The sections below take them one at a time.

MounjaroOzempic
Active ingredientTirzepatideSemaglutide
MakerEli LillyNovo Nordisk
Acts onGIP and GLP-1 receptorsGLP-1 receptor
FDA-approved forType 2 diabetes: blood sugar control (ages 10 and up), and lowering cardiovascular risk in adults at high riskType 2 diabetes in adults: blood sugar control, lowering cardiovascular risk with established cardiovascular disease, and lowering kidney and cardiovascular risk with chronic kidney disease
Approved for weight loss?No. For weight management, tirzepatide is sold as ZepboundNo. For weight management, semaglutide is sold as Wegovy
Weekly doses2.5 mg to 15 mg, in 2.5 mg steps0.25, 0.5, 1 and 2 mg
How it comesSingle-dose pen, four-dose KwikPen or vialMulti-dose pen or single-dose prefilled syringe
Maker’s self-pay priceFrom $499 a month$199 to $499 a month
With commercial insurance that covers itAs little as $25As little as $25 a month

Uses and doses are from each label.1,2 Prices are the manufacturers’ as of November 18, 2026, and can change.6,7 The cost section has the terms.

Which leads to more weight loss, Mounjaro or Ozempic?

In the trial that compared them directly in type 2 diabetes, people on Mounjaro lost more weight on average. Keep in mind that both drugs are FDA-approved for type 2 diabetes, not for weight loss. These figures come from diabetes trials.1,2

SURPASS-2, the head-to-head trial

SURPASS-2 enrolled adults with type 2 diabetes who were already taking metformin. About 470 people per group took Mounjaro 5 mg, 10 mg or 15 mg, or Ozempic 1 mg, for 40 weeks.3

GroupAverage weight lostIn poundsShare of starting weight
Mounjaro 5 mg7.6 kgAbout 17 lbAbout 8%
Mounjaro 10 mg9.3 kgAbout 21 lbAbout 10%
Mounjaro 15 mg11.2 kgAbout 25 lbAbout 12%
Ozempic 1 mg5.7 kgAbout 13 lbAbout 6%

Average change at 40 weeks, from the Mounjaro label.1 Starting weight averaged about 94 kg. Pounds are our rounded conversion. Individual results vary.

Every Mounjaro dose came out ahead of Ozempic 1 mg, and the 15 mg group lost nearly twice as much. These are averages: some people lost more and some lost less.

Two limits of that trial

  • It used Ozempic 1 mg, not 2 mg. Ozempic’s top dose was not part of SURPASS-2. In a separate 40-week trial on Ozempic’s label, adults with type 2 diabetes lost an average of 6.4 kg on 2 mg and 5.6 kg on 1 mg.2 That study had different participants, so it cannot simply be added to the table.
  • Everyone had type 2 diabetes. Trials in people without diabetes have shown larger weight changes. On Zepbound 15 mg, average loss was 20.9% without diabetes and 14.7% with it. On Wegovy, it was 14.9% and 9.6%.8,9

Without diabetes: SURMOUNT-5

SURMOUNT-5 compared the two ingredients in 751 adults with obesity and without diabetes, at the highest doses each person could tolerate of the weight-management versions, Zepbound and Wegovy. After 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.10

If you do not have type 2 diabetes and your goal is weight management, Zepbound and Wegovy are the FDA-approved products with these ingredients. Mounjaro and Ozempic are not.

How do they compare on blood sugar, heart and kidney protection?

Type 2 diabetes is what both are approved to treat, so their labels say the most here.

Blood sugar

A1C (also written HbA1c) is a blood test of average blood sugar. In SURPASS-2 it fell by 2.0, 2.2 and 2.3 percentage points on Mounjaro 5 mg, 10 mg and 15 mg, and by 1.9 points on Ozempic 1 mg. The share of people reaching an A1C below 7% was 82%, 86% and 86% on Mounjaro and 79% on Ozempic.1,3

Mounjaro led at every dose, and Ozempic’s results were strong too. In Ozempic’s own trial of its two higher doses, A1C fell by 2.1 points on 2 mg and 1.9 points on 1 mg.2

Heart

Both labels include an indication for lowering the risk of major cardiovascular events (cardiovascular death, heart attack and stroke). The wording and the evidence differ.

  • Ozempic: for adults with type 2 diabetes and established cardiovascular disease. In SUSTAIN 6, over 2.1 years, 6.6% of people on Ozempic had a major cardiovascular event, compared with 8.9% on placebo (hazard ratio 0.74, 95% confidence interval 0.58 to 0.95).2
  • Mounjaro: for adults with type 2 diabetes at high risk for these events, added in August 2026. SURPASS-CVOT compared it with dulaglutide, another diabetes medication, in 6,647 people per group over a median of 210 weeks. Major cardiovascular events occurred in 12.1% on Mounjaro and 13.0% on dulaglutide (hazard ratio 0.92, 0.83 to 1.01). Death from any cause occurred in 8.5% and 10.1% (hazard ratio 0.84, 0.75 to 0.94).1

One trial used a placebo and the other an active drug, so the two results cannot be compared with each other.

Kidneys

Only Ozempic’s label has a kidney indication: lowering the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. In the FLOW trial of the 1 mg dose, the kidney outcome occurred in 18.7% of people on Ozempic and 23.2% of the comparison group (hazard ratio 0.76, 0.66 to 0.88). The hazard ratio for cardiovascular death was 0.71 (0.56 to 0.89).2,11

Do Mounjaro and Ozempic have the same side effects?

Largely, yes. The most common side effects of both are in the stomach and gut. The table shows rates from the placebo-controlled trials on each label.

Side effectMounjaro 5 / 10 / 15 mgMounjaro trials, placeboOzempic 0.5 / 1 mgOzempic trials, placebo
Nausea12% / 15% / 18%4%15.8% / 20.3%6.1%
Diarrhea12% / 13% / 17%9%8.5% / 8.8%1.9%
Vomiting5% / 5% / 9%2%5.0% / 9.2%2.3%
Constipation6% / 6% / 7%1%5.0% / 3.1%1.5%
Abdominal pain6% / 5% / 5%4%7.3% / 5.7%4.6%
Any stomach or gut reaction37.1% / 39.6% / 43.6%20.4%32.7% / 36.4%15.3%

Share of adults reporting each reaction in pooled placebo-controlled trials.1,2 Mounjaro’s label also lists decreased appetite (5% to 11%) and indigestion (5% to 8%).

These are separate trials with different participants, so a lower number in one column does not prove one drug is gentler. The table also stops at Ozempic 1 mg. In the trial of Ozempic 2 mg and 1 mg, stomach and gut reactions were reported by 34% and 30.8%.2

Ozempic’s label notes that most nausea, vomiting and diarrhea happened while the dose was being raised. Few people stopped treatment because of stomach and gut reactions: 3.0% to 6.6% on Mounjaro and 3.1% to 3.8% on Ozempic.1,2 Both medication guides say to drink fluids when you have nausea, vomiting or diarrhea, to lower the chance of dehydration.

Warnings the two labels share

Both carry a boxed warning about thyroid C-cell tumors, seen in rodent studies. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both labels also warn about pancreatitis, gallbladder problems, kidney injury from dehydration, low blood sugar when taken with insulin or a sulfonylurea, diabetic retinopathy complications, serious allergic reactions, severe stomach reactions (neither is recommended with severe gastroparesis) and aspiration during general anesthesia or deep sedation.1,2

Get medical help for severe stomach pain that will not go away, a lump or swelling in your neck, or upper stomach pain with fever or yellowing of the skin or eyes.

Two differences

  • Birth control pills. Mounjaro’s label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.1 The highlights of Ozempic’s label do not list that step.
  • Pregnancy planning. Ozempic’s label says to stop at least 2 months before a planned pregnancy.2 Mounjaro’s says that, based on animal studies, it may cause fetal harm.

Our GLP-1 side effects guide covers what is common, what is serious and how long side effects last.

How does dosing differ between Mounjaro and Ozempic?

Both are injected once a week, and both start low and step up. The milligram numbers are very different and do not translate from one drug to the other.

MounjaroOzempic
Starting dose2.5 mg0.25 mg for 4 weeks
Steps up2.5 mg at a time, after at least 4 weeks on the current dose, if more blood sugar control is needed0.5 mg after 4 weeks. Then 1 mg and 2 mg if more blood sugar control is needed, each after at least 4 weeks
Maximum dose15 mg a week (10 mg in pediatric patients)2 mg a week
Missed doseTake it within 4 days (96 hours), otherwise skip itTake it within 5 days, otherwise skip it
Changing your injection dayDoses must be at least 3 days (72 hours) apartDoses must be more than 2 days (48 hours) apart
FormsSingle-dose pen, single-dose vial, multi-dose vial or four-dose KwikPenPens that deliver 0.25 mg or 0.5 mg doses, four 1 mg doses or four 2 mg doses. Also single-dose prefilled syringes

From each prescribing information.1,2 Your prescriber sets your dose.

  • Milligrams do not compare. These are different molecules, so 5 mg of Mounjaro is not five times 1 mg of Ozempic.
  • The top dose is a ceiling, not a goal. Both labels tie the later increases to whether more blood sugar control is needed. Ozempic’s maintenance doses are 0.5 mg, 1 mg or 2 mg.
  • Ozempic tablets are a separate product. They are taken once a day for type 2 diabetes, starting at 1.5 mg.12 Mounjaro comes only as an injection.

The Ozempic dosage guide has the full schedule, and the Mounjaro and Ozempic pages cover each drug on its own.

Mounjaro vs. Ozempic cost: what will you pay?

List prices are close: $1,112.16 per fill for Mounjaro and $1,027.51 per pen for Ozempic.5,13 What you pay depends on your insurance and on the manufacturer programs below, shown as published on November 18, 2026.

Your situationMounjaroOzempic
Commercial insurance that covers itAs little as $25 for a 1-, 2- or 3-month fill of single-dose pens with the Mounjaro Savings Card. Savings are capped at $150 per 1-month fill, $300 per 2-month fill or $450 per 3-month fill, and at $1,950 a calendar year and 13 fills.As little as $25 a month with the Ozempic savings offer. Savings are capped at $100 a month, for up to 48 months.
Commercial insurance that does not cover itAs low as $499 for a 1-month fill with the card. Savings are capped at $647 a month and $8,411 a year, up to 13 fills.The self-pay prices in the next row.
Paying yourselfFrom $499 a month for single-dose pens at every dose, through LillyDirect, with a prescription.New patients: $199 a month for the first 2 fills of 0.25 mg or 0.5 mg (through December 31, 2026). Then $349 a month for 0.25 mg, 0.5 mg or 1 mg, and $499 a month for 2 mg.
Medicare, Medicaid or other government coverageNot eligible for the card.Not eligible for the $25 offer.

Lilly and Novo Nordisk terms as of November 18, 2026.4,6,7 They change. Confirm them with the manufacturer or your pharmacy before you fill.

A condition on the Mounjaro card. The prescription must be for a use consistent with the FDA-approved labeling, which means type 2 diabetes. A Mounjaro prescription written only for weight loss does not qualify. The card counts a month as 28 days and up to four pens, and it expires December 31, 2026.4

Insurance. Each plan sets its own rules. FitRx’s insurance coordination team submits prior authorizations to commercial plans, and most decisions come back in 2 to 14 business days. FitRx does not work with Medicare, Medicaid or TRICARE. The GLP-1 insurance checker explains the process.

Compounded medication. When a provider judges it appropriate, FitRx offers compounded semaglutide from $151 a month and compounded tirzepatide from $216 a month, each with a 3-month supply, on top of membership. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness or quality. They are not generics of Ozempic or Mounjaro and were not tested in the brand-name trials.14 See the tirzepatide and semaglutide pages.

Can you switch between Mounjaro and Ozempic?

People do move from one to the other, for reasons such as side effects or a change in coverage. It is a prescriber’s decision, and three general points apply.

  • Not both at once. The label for Zepbound, which is the same tirzepatide as Mounjaro, says it is not recommended with any GLP-1 receptor agonist, and semaglutide is one.8 A switch means stopping one and starting the other.
  • No milligram-for-milligram conversion. The two are different molecules with different dose ranges. A high dose of one does not tell you the dose of the other.
  • Your provider sets the starting dose and the timing. Each label has its own starting dose and steps. How they apply after a switch is your prescriber’s judgment.

Tell your provider your current dose, any side effects, whether you take insulin or a sulfonylurea, and whether you use birth control pills. Do not change doses or swap pens on your own.

Mounjaro vs. Ozempic: which one is the better fit?

On the SURPASS-2 averages, Mounjaro lowered A1C and weight more than Ozempic 1 mg in adults with type 2 diabetes.3 That does not make it the right choice for everyone.

If this describes youWhat to raise with your provider
Type 2 diabetes, and the largest average drop in A1C and weight matters mostMounjaro led at every dose against Ozempic 1 mg.
Type 2 diabetes with chronic kidney diseaseOnly Ozempic’s label has a kidney indication.
Type 2 diabetes with established cardiovascular diseaseBoth labels have a cardiovascular indication, worded differently.
You use birth control pillsMounjaro’s label calls for a non-oral or barrier method for 4 weeks after starting and after each dose increase.
You are paying without insuranceOzempic’s listed self-pay prices are lower below the 2 mg dose (as of November 18, 2026).
No diabetes, and your goal is weight lossNeither is approved for that. Zepbound and Wegovy are.

Getting either one through FitRx

FitRx providers can prescribe Mounjaro, Ozempic, Zepbound or Wegovy when appropriate. You complete an online intake, and a U.S.-licensed provider reviews it, typically within 1 to 2 business days. Membership is $39 for the first month, then $135 a month, and medication is billed separately. Not everyone qualifies.

See if you qualify

Mounjaro vs. Ozempic: common questions

Is Mounjaro better than Ozempic for weight loss?

In SURPASS-2, the trial that compared them directly, adults with type 2 diabetes lost an average of 7.6 to 11.2 kg on Mounjaro, depending on dose, and 5.7 kg on Ozempic 1 mg over 40 weeks. Ozempic 2 mg was not tested. Neither drug is FDA-approved for weight loss, and individual results vary.

What is the main difference between Mounjaro and Ozempic?

The active ingredient. Eli Lilly makes Mounjaro, whose ingredient, tirzepatide, works on two receptors: GIP and GLP-1. Novo Nordisk makes Ozempic, whose ingredient, semaglutide, works on the GLP-1 receptor alone. Their doses, pens, approved uses and prices differ too.

Are Mounjaro and Ozempic approved for weight loss?

No. Both are FDA-approved for type 2 diabetes. Zepbound (tirzepatide, the ingredient in Mounjaro) and Wegovy (semaglutide, the ingredient in Ozempic) are the brands approved for weight management.

Is Mounjaro stronger than Ozempic?

The milligram numbers cannot be compared, because the two are different molecules. In the head-to-head trial, each Mounjaro dose lowered A1C and weight more, on average, than Ozempic 1 mg. Ozempic 2 mg was not part of that trial.

Can you switch from Ozempic to Mounjaro?

It can be done in either direction if your prescriber decides it makes sense. Doses do not convert milligram for milligram, so your provider chooses the starting dose and the timing. Do not make the change on your own.

Can you take Mounjaro and Ozempic together?

They are not meant to be combined. The label for Zepbound, which is the same tirzepatide as Mounjaro, says it is not recommended with any GLP-1 receptor agonist, and semaglutide is a GLP-1 receptor agonist.

Which has fewer side effects, Mounjaro or Ozempic?

The common ones are the same: nausea, diarrhea, vomiting, constipation and abdominal pain. In each label's own trials, nausea was reported by 12% to 18% of people on Mounjaro and 15.8% to 20.3% on Ozempic 0.5 mg and 1 mg. Those were separate trials, so it is not a direct comparison.

Which costs less, Mounjaro or Ozempic?

With commercial insurance that covers the drug, either can cost as little as $25 with the manufacturer's savings program. Paying yourself, as of November 18, 2026, Ozempic is listed at $349 a month for doses up to 1 mg and $499 for 2 mg, and Mounjaro starts at $499 a month. Confirm current prices before you fill.

Can I use the Mounjaro Savings Card for a weight loss prescription?

No. The card requires a prescription for a use consistent with Mounjaro's FDA-approved labeling, which is type 2 diabetes. A prescription written only for weight loss does not qualify, and people on government insurance are excluded too.

References (14)
  1. Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
  2. Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
  3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
  4. Eli Lilly and Company. Mounjaro savings and coverage, including Savings Card terms and conditions. https://mounjaro.lilly.com/savings-coverage
  5. Novo Nordisk. NovoCare: Ozempic savings offer and list price. https://www.novocare.com/diabetes/products/ozempic/savings-offer.html
  6. Eli Lilly and Company. LillyDirect: Mounjaro self-pay pricing and pharmacy options. https://www.lilly.com/lillydirect/medicines/mounjaro
  7. Novo Nordisk. Save on Ozempic: savings offer, self-pay prices and Medicare information. https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
  8. Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  9. Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
  10. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
  11. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. https://pubmed.ncbi.nlm.nih.gov/38785209/
  12. Rybelsus and Ozempic (semaglutide) tablets. Prescribing information. Novo Nordisk; revised January 2026. https://www.novo-pi.com/ozempictablets.pdf
  13. Eli Lilly and Company. Mounjaro pricing information (list price). https://pricinginfo.lilly.com/mounjaro
  14. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.

Not sure which one fits? Start with a provider.

Answer a few questions online. A licensed FitRx provider reviews your health history and tells you whether a GLP-1 medication is appropriate for you, and which one.

Get started

FitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.

A person messaging their FitRx care team in the patient portal on a phone

The FitRx care team

A comparison chart cannot read your health history

Trial averages and price tables narrow the question. They do not answer it for you. A U.S.-licensed FitRx provider looks at your diagnoses, your other medications and your coverage before recommending Mounjaro, Ozempic, a weight-management brand or no medication at all.

  • U.S.-licensed providers review every intake and make every prescribing decision
  • Unlimited secure messaging, plus monthly video or phone visits
  • A care coordinator and a coach alongside your provider
  • An insurance coordination team for brand-name GLP-1 prior authorizations

This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.

GLP-1 medications our providers can prescribe

A provider decides which medication, if any, fits your health history. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as the brand-name products.